Daily Management Review

Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents


10/22/2016


GSK seeks for ways to “contribute” in easing “access to medicines” worldwide.



Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents
Last week, GlaxoSmithKline, the giant among the “London-listed pharmaceuticals”, reported of its “evolving” approach towards “filing and enforcing patents”, whereby reflecting “a country’s wealth” through “IP protection”.
 
Before the “UN High Level Panel” meeting discussing on “Access to Medicines”, the pharmaceutical informed that it will not “file patents for its medicines” in the countries where the either the income is low or is among the “least developed” countries. In this way, other companies will get a chance to create “cheaper generic versions” of Glaxo’s medicines for selling in those countries.
 
However, when the question comes to the “lower middle income countries”, Glaxo decides to file patent, although it will be offer license or agree to allow license for the sale of “generic versions of its medicines” over a decade. In fact, Glaxo has plans of seeking a small portion of royalty on the above mentioned sales.
 
Eventually, for the “high income”, “upper middle income” as well as G20 countries, Glaxo will maintain its “full patent protection”, while:
“Any Glaxo drugs on the WHO’s list of essential medicines will be included in these changes”.
 
In the words of the chief executive e officer of Glaxo, Sir Andrew Witty:
“In itself, IP is not a barrier to access to medicines. However, we recognise that the global healthcare challenge requires us to be flexible in our approach and responsive to different needs, particularly as the disease burden shifts from infectious to non-communicable diseases.
“We continuously look at ways that GSK can further contribute to increasing access to medicines.”
 
Moreover, Glaxo made an announcement of allowing the “developing countries” to access its “next-generation cancer drugs”, whereby it will allow “competitors to access its intellectual property through the UN-backed Medicines Patent Pool”.
 
 
 
 
 
 
References:
http://www.digitallook.com/







Science & Technology

Asteroid mining: Reality or fiction?

3D Printing Used For Life Saving Kidney Transplant In Two Year Old At U.K. NHS

California to require solar panels for new homes by 2020

Blockchain Enables De Beers To Track Diamond From The Miner To The Retailer

Microsoft releases Windows 10’s April 2018 Update

DNA Sequencing Project Proposed For All Complex Life Forms On Earth By An Int’l Team

Facebook may start production of its own microprocessors

Long-Term Alcohol Monitoring Could Be Possible With A New Injectable Chip Developed By U.S. Researchers

Sweden Now Has The First Electrified Road In The World

Over 270,000 Account Globally Banned From Twitter For Promotion Of Terrorism

World Politics

World & Politics

Ministerial Visit From India To North Korea Aimed At Strengthening Ties

What countries are the biggest losers of Trump’s Iran decision?

World's Oldest Elected Prime Minister Is Malaysia’s 92 Year Old Mahathir Mohamad

Why Is U.S. Pulling Out Of The Iran Deal A Big Deal For The World

Merkel, Macron, May call on Iran to adhere to the nuclear deal

Arab Region Driven In ‘Wrong Direction’ In Last 10 Years, Say Arab Your: Survey

German doctors demand a tax on sugar

U.S.-China Ties Could Be Bettered By AI As The Bridge: Experts